Firefly Neuroscience Inc (AIFF) - EV/EBITDA Multiple
The current price chart for Firefly Neuroscience, Inc (AIFF) shows an EV/EBITDA ratio of 0.00, while the business generates revenue from B2B subscriptions for cloud-based brain mapping software, ensuring high margins. Firefly Neuroscience, Inc is implementing the BNA system to diagnose depression and ADHD via digital markers. The project is currently in the launch phase, meaning operational cash flow remains limited to framework agreements.
AIFF (fireflyneuro.com): analytical breakdowns and indicator data
- market price and analyst price targets:
- market capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Equity Ratio Firefly Neuroscience, Inc|AIFF - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Firefly Neuroscience|AIFF - Aggregate Debt Obligations|Debt to Book Capitalization Ratio AIFF|AIFF - Company Long-Term Indebtedness|Company Short-Term Debts Firefly Neuroscience|Quick Liquidity Indicator fireflyneuro.com
- financial results and valuation multiples details:
AIFF - Net Profit|Expected Profit Firefly Neuroscience, Inc|AIFF - Company Value to Net Income|Future Price to Earnings Firefly Neuroscience, Inc|AIFF - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization AIFF|AIFF - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Firefly Neuroscience|AIFF - Net earnings per share for the last 12 months|Quarterly EPS earnings growth fireflyneuro.com|AIFF - Expected net earnings per share growth this year|Earnings growth forecast for next year Firefly Neuroscience, Inc
Summary company analysis:AIFF (Firefly Neuroscience Inc)
The resilience of Firefly Neuroscience, Inc (AIFF) is based on the creation of an ecosystem comprising AI diagnostics and recurring payments for consumables and cloud services. The company's EV/EBITDA ratio, accounting for debt load, correlates the total enterprise value with operating profit before depreciation and interest, allowing investors to assess the real value of assets relative to generated cash flow and determine the extent of the stock's premium.
Competitor analysis for Firefly Neuroscience, Inc
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Corp BIIB|Business Value to Operating Income Before Depreciation NBIX|Regencell Bioscience - EV/EBITDA Multiple|Company Value to EBITDA axsome.com|ACAD: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio XENE (Xenon Pharmaceuticals Inc.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Viking Pharma|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SUPN|Enterprise Value to EBITDA Ratio CPRX (Catalyst Pharmaceuticals)|DNLI - Company Value to EBITDA|Harmony Biosciences Holdings, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BHVN|AMLX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TRVI (Trevi Corp) - Enterprise Value to Operating Income Before Depreciation|PRAX: EV/EBITDA Multiple|Company Value to EBITDA anavex.com (AVXL)|Enterprise Value to EBITDA Ratio CBLL|EV/EBITDA Multiple Prothena Corporation PLC|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alector, Inc. (ALEC)|ANNX (Annexon Biosciences Inc.) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omeros OMER|neurogene.com (NGNE) - Company Value to EBITDA|ACIU - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Voyager Therapeutics Inc VYGR|NMRA: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Scilex Holding Company, Inc.|TVGN (Tevogen Bio Holdings) - EV/EBITDA Multiple|Alpha Cognition Corp (ACOG) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CGTX|IKT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cassava SAVA|ASRT: Enterprise Value to Operating Income Before Depreciation|Coya - EV/EBITDA Multiple|Vistagen Therapeutics (VTGN) - Enterprise Value to EBITDA Ratio|OVID: EV/EBITDA Multiple|Company Value to EBITDA Acumen Pharmaceuticals Inc. (ABOS)|Enterprise Value to EBITDA Ratio CRVO|ATHE: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple CLNN|Total Company Value to Operating Income Before Depreciation Ratio pepgen.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jupiter Neurosciences JUNS|RLMD: Enterprise Value to Operating Income Before Depreciation|Annovis Bio Corp - EV/EBITDA Multiple|Grace Therapeutics, Inc. (GRCE) - Enterprise Value to EBITDA Ratio|KLTO: EV/EBITDA Multiple|NeuroSense Therapeutics Ltd. (NRSN) - EV/EBITDA Multiple|RVPH (Reviva Pharmaceuticals Holdings, Inc.) - EV/EBITDA Multiple|MetaVia, Inc. (MTVA) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple NRXS|HSDT: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PASG (Passage Bio)|NEUP (Neuphoria Therapeutics, Inc.) - Company Value to Operating Income Before Depreciation Ratio|NERV - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ATHA (Athira Pharma Inc) - Enterprise Value to Operating Income Before Depreciation|ADXN: EV/EBITDA Multiple|Company Value to EBITDA Alzamend Neuro (ALZN)|Enterprise Value to EBITDA Ratio CYCN|EV/EBITDA Multiple Protagenic|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pasithea Therapeutics (KTTA)|CRGT (cortigent.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Avenue Therapeutics, Inc ATXI|BrainStorm Cell Therapeutics Inc. (BCLI) - Company Value to EBITDA|Cara Therapeutics, Inc. - EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio CHRO|ELYM: EV/EBITDA Multiple|ITCI - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Longboard Pharma|MRNS: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple NKGN|NRBO - Company Value to EBITDA|EV/EBITDA Multiple SAGE (Sage Therapeutics)|SNPX (Synaptogenix Inc.) - Company Value to Operating Income Before Depreciation Ratio|TRVN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VIGL: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|WENA (Anew Medical, Inc.) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA cerevel.com (CERE)
